B. Riley Reduces Earnings Estimates for TG Therapeutics

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities research analysts at B. Riley lowered their FY2027 earnings per share estimates for shares of TG Therapeutics in a report released on Monday, November 4th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will earn $2.46 per share for the year, down from their previous estimate of $2.48. B. Riley has a “Buy” rating and a $34.00 price objective on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.13 per share. B. Riley also issued estimates for TG Therapeutics’ FY2028 earnings at $3.41 EPS.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). The firm had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.65%. The firm’s quarterly revenue was down 49.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.73 EPS.

A number of other research firms have also recently commented on TGTX. The Goldman Sachs Group boosted their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday. TD Cowen started coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price objective for the company. Finally, HC Wainwright lifted their target price on shares of TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.67.

TG Therapeutics Price Performance

NASDAQ:TGTX opened at $27.90 on Thursday. The stock has a market capitalization of $4.32 billion, a PE ratio of -278.97 and a beta of 2.19. TG Therapeutics has a 52 week low of $9.81 and a 52 week high of $28.41. The company has a quick ratio of 2.83, a current ratio of 3.58 and a debt-to-equity ratio of 0.58. The stock’s 50-day moving average price is $23.73 and its 200-day moving average price is $20.36.

Hedge Funds Weigh In On TG Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Assenagon Asset Management S.A. acquired a new stake in TG Therapeutics in the 2nd quarter valued at about $8,698,000. Marshall Wace LLP purchased a new position in TG Therapeutics during the second quarter worth approximately $36,501,000. Raymond James & Associates boosted its stake in TG Therapeutics by 35.9% during the third quarter. Raymond James & Associates now owns 170,160 shares of the biopharmaceutical company’s stock worth $3,980,000 after buying an additional 44,972 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in TG Therapeutics by 13.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 503,645 shares of the biopharmaceutical company’s stock valued at $8,960,000 after buying an additional 59,523 shares in the last quarter. Finally, Cetera Advisors LLC acquired a new stake in shares of TG Therapeutics in the 1st quarter worth $622,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.